Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Return on Capital Employed (2019 - 2026)

10x Genomics' Return on Capital Employed history spans 7 years, with the latest figure at 6.92% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 1708.0% to 6.92% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.92%, a 1708.0% increase, with the full-year FY2025 number at 7.38%, up 1623.0% from a year prior.
  • Return on Capital Employed hit 6.92% in Q4 2025 for 10x Genomics, up from 10.66% in the prior quarter.
  • Over the last five years, Return on Capital Employed for TXG hit a ceiling of 5.84% in Q4 2021 and a floor of 63.87% in Q1 2021.
  • Historically, Return on Capital Employed has averaged 25.12% across 5 years, with a median of 20.6% in 2023.
  • The widest YoY moves for Return on Capital Employed: up 5571bps in 2021, down -5524bps in 2021.
  • Tracing TXG's Return on Capital Employed over 5 years: stood at 5.84% in 2021, then crashed by -226bps to 19.05% in 2022, then tumbled by -68bps to 31.98% in 2023, then increased by 25bps to 24.0% in 2024, then surged by 71bps to 6.92% in 2025.
  • Business Quant data shows Return on Capital Employed for TXG at 6.92% in Q4 2025, 10.66% in Q3 2025, and 12.12% in Q2 2025.